bioRxiv (Cold Spring Harbor Laboratory)
December 16, 2024
Jan C. Gendra, Edmundo Lopez-Sola, Francesca Castaldo et al.
7 citations
preprint
Abstract Classical serotonergic psychedelics show promise in addressing neurodegenerative disorders such as Alzheimer’s disease by modulating pathological brain dynamics. However, the precise neurobiological mechanisms underlying their effects remain elusive. This study introduces a personalized whole-brain model built upon a laminar neural mass framework to elucidate these effects. Using...
Emerging Trends in Drugs, Addictions, and Health
December 14, 2024
Eline Pottie, Grant C. Glatfelter, Michael H. Baumann et al.
Introduction: Serotonergic psychedelics induce their characteristic subjective effects via activation of the serotonin 2A receptor (5-HT2AR). This structurally diverse class of drugs includes ergolines (e.g., LSD), phenethylamines (e.g., mescaline), and tryptamines (e.g., psilocin), all of which have NPS analogues that have emerged on recreational drug markets. Importantly, certain ergolines...
bioRxiv Preprint Server
December 12, 2024
Lauri Elsilä, Elina Nagaeva, Jari-Pekka Luukkonen et al.
1 citation
preprint
The current research on psychedelic compounds such as lysergic amide diethylamide (LSD) is leaning heavily on the notion that psychedelics are not addictive. While much of the literature supports this argument, some of the common use patterns and the descriptions of the subjective effects of these compounds in humans, together with rather lacking and mixed data from non-human animal studies...
Network Neuroscience
December 10, 2024
Thomas F. Varley, Daniel Havert, Leandro Fosque et al.
12 citations
Most of the recent work in psychedelic neuroscience has been done using noninvasive neuroimaging, with data recorded from the brains of adult volunteers under the influence of a variety of drugs. While these data provide holistic insights into the effects of psychedelics on whole-brain dynamics, the effects of psychedelics on the mesoscale dynamics of neuronal circuits remain much less...
The British Journal of Psychiatry
December 5, 2024
Emma S Høgsted, Vincent Beliveau, Brice Ozenne et al.
4 citations
Background Using [ 18 F]altanserin, a serotonin 2A receptor (5-HT 2A R) antagonist Positron Emission Tomography (PET) tracer, a positive association between cortical 5-HT 2A R binding and the inward-directed facets of neuroticism has been demonstrated in healthy individuals. Psilocybin, a 5-HT 2A R agonist, shows promise for the treatment of depression, reducing neuroticism and mood symptoms...
Molecular Psychiatry
December 1, 2024
Chloe E Page, C Neill Epperson, Andrew M Novick et al.
54 citations
The serotonin deficit hypothesis explanation for major depressive disorder (MDD) has persisted among clinicians and the general public alike despite insufficient supporting evidence. To combat rising mental health crises and eroding public trust in science and medicine, researchers and clinicians must be able to communicate to patients and the public an updated framework of MDD: one that is (1)...
British Journal of Pharmacology
December 1, 2024
Yong-Yu Yin, Jiao-Zhao Yan, Qian-Qian Wei et al.
13 citations
The emerging antidepressant effects of ketamine have inspired tremendous interest in its underlying neurobiological mechanisms, although the involvement of 5-HT in the antidepressant effects of ketamine remains unclear. The chronic restraint stress procedure was performed to induce depression-like behaviours in mice. OFT, FST, TST, and NSFT tests were used to evaluate the antidepressant-like...
Pharmacology, Biochemistry, and Behavior
December 1, 2024
Lucie Olejníková-Ladislavová, Michaela Fujáková-Lipski, Klára Šíchová et al.
5 citations
Mescaline is a classical psychedelic compound with a phenylethylamine structure that primarily acts on serotonin 5-HT2A/C receptors, but also binds to 5-HT1A and 5-HT2B receptors. Despite being the first psychedelic ever isolated and synthesized, the precise role of different serotonin receptor subtypes in its behavioral pharmacology is not fully understood. In this study, we aimed to...
Journal of Cerebral Blood Flow & Metabolism
November 29, 2024
Frederick A. Bagdasarian, Kristian Larsen, Deng Hong et al.
1 citation
Understanding neuromodulatory effects of serotonin 2A receptor (5-HT 2A R) agonists with diverse pharmacological profiles is relevant to advancing psychedelic-related drug applications. We performed simultaneous positron emission tomography (PET) and pharmacological magnetic resonance imaging (phMRI) in anesthetized nonhuman primates (NHP; N = 3) to examine partial agonists with varying 5-HT 2A...
Pharmacological Reports
November 27, 2024
Ewelina Cyrano, Piotr Popik
Serotonergic psychedelics, which display a high affinity and specificity for 5-HT2A receptors like 2,5-dimethoxy-4-iodoamphetamine (DOI), reliably induce a head-twitch response in rodents characterized by paroxysmal, high-frequency head rotations. Traditionally, this behavior is manually counted by a trained observer. Although automation could simplify and facilitate data collection, current...